Loading stock data…
Fresenius SE & Co. KGaA I (FRE.DE)
€39.44-0.38 (-0.95%)
Market ClosedLast close Jun 29
Fresenius SE & Co.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fresenius SE & Co. KGaA in the Healthcare sector is trading at €39.44 with a market capitalization of $21.0B. Wall Street consensus targets €54.22 (14 analysts), implying a +37.5% move over the next 12 months. The stock is currently 26% below its 52-week high of €52.96, remaining 11.5% below its 200-day moving average. Risk note: RSI 81 is overbought against a weak tape. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +37.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 81 against a weak tape — risk of pullback
Quarterly Financials
| Metric (EUR) | Q4 2024 | Q1 2025 | Q2 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | €5.63B↓ | €5.71B↑ | €5.58B↓ | €6.16B↑ | €5.82B |
| Gross Profit | €1.42B | €1.41B↓ | €1.46B↓ | €1.52B↓ | €1.53B |
| Operating Income | €469.00M↓ | €689.00M↑ | €560.00M↑ | €468.40M↓ | €601.00M |
| Net Income | €240.00M↑ | €229.00M↓ | €330.00M↓ | €361.00M↓ | €435.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The F...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€20.99B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.91
Beta
Defensive asset. Lower volatility than the S&P 500.
0.83
Div Yield
Strong income play. Yield provides a meaningful total return floor.
279.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.79%
Volume
Today's trading volume
828,956
Recent News
Fresenius Medical Care dips after US proposes lower dialysis reimbursement rate
Investing.com -- Shares in Fresenius Medical Care (ETR:FMEG) fell about 5% Thursday after U.S. health regulator CMS proposed a smaller-than-expected increase to dialysis reimbursement rates and moved to bundle a key drug category into its payment system.
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Fresenius (FMS) Q1 2026 Earnings Transcript
Helen Giza: Thank you, Dominik. Thank you for your continued interest in Fresenius Medical Care. On 30th of April, we successfully completed our initial share buyback program of EUR 1 billion in a significantly accelerated way.
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How The Fresenius SE KGaA (XTRA:FRE) Investment Story Is Evolving With Mixed Analyst Targets
The fair value estimate for Fresenius SE KGaA was trimmed slightly from €55.90 to €55.47 per share, a modest adjustment of about €0.43. This shift lines up with Street research that combines higher targets from bullish houses and €1 to €2 cuts from more cautious analysts, leaving the overall picture more balanced than before. As you read on, you will see how these different calls shape the evolving narrative around risk, reward, and what to watch next. Analyst Price Targets don't always...